Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Heterozygous Familial Hypercholesterolemia: full-pipeline trial registry
1 of 5 indexed Heterozygous Familial Hypercholesterolemia trials are currently recruiting.
Corpus placement: #3,391 of 28,707 conditions by registered trial count.
5 US clinical trials · 1 currently recruiting · #3,391 of 28,707 conditions by registered trial count
Heterozygous Familial Hypercholesterolemia: 5 US clinical trials tracked, 1 recruiting.
Heterozygous Familial Hypercholesterolemia is the subject of 5 registered US clinical trials on ClinicalTrials.gov, 1 of them currently open to new participants. 3 are in Phase 3-4 (later-stage) and 2 in Phase 1-2 (earlier-stage). The most active sponsor is Regeneron Pharmaceuticals, running 2 of these trials.
Enrollment posture brief
Registry condition heterozygous-familial-hypercholesterolemia
OPEN 1 | RECR 20% | LATE 3 | EARLY 2 | RANK #3391 | SPON 2
Volume-matched condition peers
Nearest open-share peer: Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive (20% recruiting · 10 trials)
Heterozygous Familial Hypercholesterolemia lists 1 open slots (20% of 5 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Heterozygous Familial Hypercholesterolemia on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Heterozygous Familial Hypercholesterolemia is recruiting below its size-band peers.
1 of 5 indexed trials (20%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
One sponsor concentrates Heterozygous Familial Hypercholesterolemia research.
Regeneron Pharmaceuticals accounts for 2 of 5 trials (40%). 4 distinct sponsors appear on at least one study for this condition label.
-
Most Heterozygous Familial Hypercholesterolemia trials plan to enrol fewer than 100 people.
Median target enrolment is 85 among the 5 trials that report a genuine target (sentinel values excluded). 3 of those (60%) plan for fewer than 100 participants.
-
Heterozygous Familial Hypercholesterolemia research is mostly interventional.
5 interventional and 0 observational studies make up this index (100% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
5 total, page 1 of 1
A Study of VERVE-102 in Patients With Familial Hypercholesterolemia or Premature Coronary Artery Disease
Verve Therapeutics
NCT06164730
Study to Assess the Efficacy and Safety of LIB003 in HeFH Patients on Oral Lipid Therapy Needing Further LDL-C Reduction
LIB Therapeutics
NCT04797104
A 52 Week Study To Assess The Use Of Bococizumab (PF-04950615; RN316) In Subjects With Heterozygous Familial Hypercholesterolemia
Pfizer
NCT01968980
Study of Alirocumab (REGN727/SAR236553) in Patients With Heterozygous Familial Hypercholesterolemia (HeFH) Undergoing Low-density Lipoprotein (LDL) Apheresis Therapy
Regeneron Pharmaceuticals
NCT02326220
Open-Label Extension of Study R727-CL-1003 (NCT01266876) to Evaluate the Long-Term Safety and Efficacy of Alirocumab (REGN727) in Participants With Heterozygous Familial Hypercholesterolemia (HeFH)
Regeneron Pharmaceuticals
NCT01576484
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 1 |
| Phase 2 | 1 |
| Phase 3 | 3 |
Top Sponsors
Named interventions
Most-linked intervention names on Heterozygous Familial Hypercholesterolemia records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Heterozygous Familial Hypercholesterolemia trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Heterozygous Familial Hypercholesterolemia page
5 registered trials, 1 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 1 Heterozygous Familial Hypercholesterolemia trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Regeneron Pharmaceuticals sponsors the most Heterozygous Familial Hypercholesterolemia trials on record, review their full trial history before evaluating a specific study. See Regeneron Pharmaceuticals's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Heterozygous Familial Hypercholesterolemia condition card totals 5 registered trials; most-linked intervention Alirocumab; top US site state Texas. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.